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Abstract
Background—Efforts to scale-up HIV treatment in high burden countries have resulted in wider 
access to care, improved survival and decreased morbidity for HIV-infected children. The country 
of Rwanda has made significant achievements in expanding coverage of pediatric HIV services.
Methods—We describe the extent of and factors associated with mortality and lost to follow-up 
(LTF) in children (<15 years) enrolled in HIV care at 39 ICAP-supported facilities across Rwanda 
from 2004 to 2010 by antiretroviral treatment (ART) status. We estimated the 1-year cumulative 
incidence of death and LTF among all children enrolled in care (pre-ART) and children on ART. 
Survival analysis was used to evaluate factors associated with death and LTF in both groups.
Results—Between January 2004 and June 2010, 3244 children with a median age of 5.7 years 
(interquartile range 2.8–9.6) enrolled in HIV care. One-year cumulative incidence for death and 
LTF among pre-ART children was 4% (95% confidence interval [CI]: 3–5%) and 5% (95% CI: 4–
6%), respectively. Overall, 2035 (63%) children initiated ART, median age 6.3 years (interquartile 
range 3.3–10.4): 1-year Kaplan–Meier estimates of death and LTF were 3% (95% CI: 3–4%) and 
1% (95% CI: 1–2%), respectively. Factors associated with an increased hazard for death among 
pre-ART children included being <18 months old versus ≥5 years (adjusted sub hazard ratio 
[aSHR] = 4.4, 95% CI: 2.9–6.8) and World Health Organization stage IV versus I (aSHR = 4.1, 
95% CI: 2.0–8.4), whereas children entering care through prevention of mother-to-child 
transmission had lower hazard than those from voluntary counseling and testing (aSHR = 0.50, 
95% CI: 0.25–1.0). Markers of advanced disease, including severe immunosuppression (aSHR = 
0.25, 95% CI: 0.12–0.54), and enrollment in care in rural versus urban clinics (aSHR = 0.71, 95% 
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CI: 0.53–0.97) were protective against LTF. For children on ART, factors associated with hazard of 
death included younger age (adjusted hazard ratio [aHR] <18 months versus ≥5 years = 2.1, 95% 
CI: 1.3–3.6), severe malnutrition versus not malnourished (aHR = 3.2, 95% CI: 1.3–8.1), advanced 
World Health Organization stage (aHR IV versus I = 9.8, 95% CI: 3.5–27.4) and severe 
immunodeficiency versus no evidence (aHR = 2.3, 95% CI: 1.7–3.3). No associations were 
observed with LTF among children on ART.
Conclusions—The results demonstrate very high retention among children enrolled in HIV care 
in Rwanda. Younger children continue to be particularly vulnerable, underscoring the urgent need 
for early identification, rapid treatment initiation and long-term retention in care.
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The country of Rwanda has made outstanding achievements toward the goal of universal 
access to antiretroviral therapy (ART) for both adults and children with HIV. Of the 
estimated 22,000 children in Rwanda living with HIV in 2011, 11,000 were estimated to 
qualify for ART, and more than 7500 (68%) had been initiated on treatment.1 In efforts to 
increase uptake of ART and to improve retention in care, the Rwandan Ministry of Health 
decentralized pediatric HIV services in 2006 to lower level health facilities2 and has worked 
with implementing partners to expand HIV services from 31 facilities in 2004 to 336 in 
2011.1 However, little has been described on the outcomes of children living with HIV in 
Rwanda.
Despite the known efficacy of ART, deaths in children after the start of ART remain high in 
sub-Saharan Africa, attributed to treatment initiation at advanced immunologic and clinical 
disease stages.3–9 Loss to follow-up (LTF) is also a significant barrier to achieving optimal 
outcomes, although data on retention in children are limited, particularly for children not on 
ART (pre-ART). Reported rates of LTF for pediatric cohorts range widely; in a pooled 
analysis of children on ART at 10 clinical sites in Southern Africa, LTF rates ranged from 
1.9% to 14.2%.10 Age and whether the child is on ART or awaiting treatment have been 
associated with LTF in other African settings.7,11
Given the high ART coverage achieved among HIV-infected children in Rwanda, the 
outcomes of children enrolled in HIV care might be different compared with other sub-
Saharan African countries. In this article, we describe the extent of and factors associated 
with mortality and LTF in children less than 15 years of age enrolled in HIV care at 39 
healthcare facilities in Rwanda from 2004 to 2010.
METHODS
Study Design and Study Population
Analysis was performed on de-identified routinely collected data on ART-naïve HIV-
infected children (<15 years old) enrolled at 39 healthcare facilities in Rwanda from January 
2004 to June 2010. These facilities, located in Kigali and the western provinces, represented 
12% of all clinics providing ART in the country and approximately one-third of the children 
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enrolled in HIV care by June 2011.12 All facilities included in this analysis received support 
from ICAP, a President’s Emergency Plan for AIDS Relief implementing partner that has 
been supporting HIV prevention, care and treatment in sub-Saharan Africa since 2005. 
Routinely collected information from patient charts was recorded at each clinic visit by 
clinicians on national forms. Data were entered into an electronic database at the health 
facility by trained data clerks, with information de-identified for analysis. Data quality 
assessments were conducted every 6 months to assess completeness and accuracy of the 
database.
Pediatric Guidelines for HIV Care and Treatment
National guidelines in place during this period recommended a comprehensive history, 
physical examination and CD4+ cell count (CD4+) at the first visit followed by monthly 
evaluations and twice yearly CD4+ monitoring.13–15 The coverage in CD4+ machines has 
been gradual over the observation period, and by 2011 all referral and district hospitals had a 
CD4 machine. Health centers coordinated with their district hospitals to transport the 
samples on specific days for CD4+ measurement. CD4+ percentages were generally not 
available as laboratories were not equipped to provide those values until recently. All HIV 
services were provided free of charge. National guidelines for ART eligibility were revised 
in 2007 and 2010.14,15 According to the 2010 guidelines, ART eligibility criteria included 
the following: (1) all children <18 months, (2) World Health Organization (WHO) stages 
III/IV, (3) WHO stage I/II and CD4+ <1500 cells/µL for children 19–36 months of age and 
(4) CD4+ count <1000 cells/µL for children 36–59 months of age or CD4+ count <350 
cells/µL for children ≥60 months of age.15 ART was prescribed by a physician according to 
national protocols, and follow-up was conducted by trained nurses. An appointment list was 
used to schedule monthly appointments. At the end of each day, the appointment list was 
checked to identify appointment defaulters who were traced by phone or home visits by the 
facility team or by peer educators. If recovered, defaulters were assessed for the reasons of 
missing their appointments, appropriately counseled and readmitted in the program.
Definitions
LTF was defined as not having had a clinic, laboratory or pharmacy visit in the 12 months 
before the date of closure of the database for pre-ART children (ie, July 2010 to June 2011) 
and in the 6 months before the date of closure of the database for children on ART (ie, Jan 
2011 to June 2011). Follow-up time on pre-ART was defined as the time between date of 
enrollment into care and ART initiation, transfer, known death, LTF or completion of the 
observation period. Follow-up time on ART was defined as the time between date of ART 
initiation and transfer, known death, LTF or completion of the observation period. For 
characteristics at enrollment into care (ie, weight, WHO stage, CD4+), any value within 3 
months of enrollment was used. For characteristics at ART initiation, we considered the 
closest value using a window period of 3 months before and 1 month after the date of ART 
initiation. Immunodeficiency was defined based on age-adjusted CD4+ according to the 
Centers for Disease Control and Prevention 1994 classification system: no evidence of 
immune suppression (<12 months: ≥1500 cells/µL; 1–5 years: ≥1000 cells/µL; ≥5 years: 
≥500 cells/µL); evidence of moderate suppression (<12 months: 750–1499 cells/µL; 1–5 
years: 500–999 cells/µL; ≥5 years: 200–499 cells/µL); and severe suppression (<12 months: 
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<750 cells/µL; 1–5 years: <500 cells/µL; ≥5 years: <200 cells/µL).16 Weight-for-age Z 
scores were calculated based on the Centers for Disease Control and Prevention standards; 
children were classified as not malnourished (Z score > −2), moderately malnourished (−2 ≥ 
Z score ≥ −3) and severely malnourished (Z score < −3).17 A substantial proportion of 
children had missing information on CD4+, WHO stage and weight; they were included in 
our analyses and assigned to “missing” categories.
Statistical Analysis
We describe characteristics at enrollment into care of all children enrolled between January 
2004 and June 2010 and at ART initiation among the subset that subsequently started ART 
between January 2004 and December 2010. For each group, we stratified characteristics by 
the age groups specified in the national Rwanda guidelines (<18 months, 18–59 months and 
≥5 years). We then examined factors associated with LTF and known deaths among pre-ART 
children and ART children. In the pre-ART model, children who initiated ART were 
censored at the date of ART initiation. In both models, children who were LTF were 
censored 15 days after their last recorded visit and children having transferred to another 
clinic were censored at their recorded date of transfer. For pre-ART children, we constructed 
subdistribution hazards models using the methods outlined by Fine and Grey to account for 
the competing risk of initiating ART.18 ART initiation was treated as a competing risk in the 
pre-ART analysis as it alters the probability of being dead or LTF.19 For children who started 
ART, the Cox proportional hazards models accounting for within-clinic correlation were 
used to examine factors associated with LTF and known deaths among children on ART. 
Variables significant at the 0.20 level in the bivariate models were included in the 
multivariate survival analyses and retained if significant at the 0.05 level based on the 
likelihood ratio test using a backward stepwise procedure. We report 1-year and 2-year death 
and LTF cumulative incidence estimates for pre-ART and Kaplan–Meier (KM) estimates for 
ART. The log-rank test was used to compare differences on the estimates for death and LTF 
by age and type of facility among pre-ART children and ART children. Data were analyzed 
using SAS 9.2 (SAS Institute, Cary, NC) and STATA 11 (StataCorp, College Station, TX) 
for the competing risk model.
Ethical Considerations
This study is part of the Identifying Optimal Models of HIV Care and Treatment 
Collaboration, which was approved by the Rwandan National Ethics Committee, the 
Columbia University Medical Center Institutional Review Board, the US Centers for Disease 
Control and Prevention and President’s Emergency Fund for AIDS Relief Office of the 
Global AIDS Coordinator.
RESULTS
Children Enrolled in HIV Care
Between January 2004 and June 2010, 3244 ART-naïve children enrolled in HIV care at 39 
facilities, including 26 health centers, 9 district hospitals, 3 referral hospitals and 1 private 
hospital. Nearly two-thirds (60%) of the facilities were in rural settings and 44% of the 
children received care in rural settings (Table 1). Annual enrollment of children increased 
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from 107 in 2004 to 783 in 2007 and then declined each year thereafter. At enrollment, 50% 
of subjects were female, the median age was 5.7 (interquartile range [IQR] 2.8–9.6), 363 
(11%) were <18 months old, 1057 (33%) were 18–59 months old and 1824 (56%) were ≥5 
years old. Four percent of the children were transferred in from another facility, and 72% of 
them were ≥5 years old. Only 7% of children enrolled in care through prevention of mother-
to-child transmission (PMTCT), of which 54% were <18 months old. Of children with a 
WHO stage at enrollment (91%), 47% had a WHO stage III/IV. Among the 2820 (87%) 
children with a CD4+ recorded at enrollment, 870 (31%) had evidence of immunodeficiency 
and 442 (16%) had severe immunodeficiency. The median follow-up time during the pre-
ART period was 5.2 months (IQR 1.0–20.3). Of those pre-ART, 143 (4%) died, 334 (10%) 
transferred to another facility, 2035 (63%) initiated ART, 191 (6%) were LTF and 541 (17%) 
remained in pre-ART care at the end of the observation period (Fig. 1). One-year cumulative 
incidence for death and LTF among all children enrolled in care was 4% (95% confidence 
interval [CI]: 3–5%) and 5% (95% CI: 4–6%), respectively. Two-year cumulative incidence 
for death and LTF among all children enrolled in care were 5% (95% CI: 4–5%) and 6% 
(95% CI: 5–7%), respectively. Among the 1209 who did not initiate ART during this period, 
293 (24%) were severely immunosuppressed or had a WHO stage III/IV at their last visit, of 
which 81 (28%) died and 48 (16%) were LTF (results not shown).
Children on ART
Overall, 2035 (63%) children initiated ART; 48% were female, the median age was 6.3 years 
[IQR 3.3–10.4] and 8% were ≤18 months old (Table 2). The number of children starting 
ART was highest in 2007 with 477 children newly initiating ART. Fifty-seven percent of the 
children had a recorded weight at ART initiation, of which 503 (43%) were severely 
malnourished based on weight-for-age Z scores. Of those with a WHO stage at ART 
initiation (98%), 65% were WHO stage III or IV. Among those with a CD4+ at ART 
initiation (84%), 24% were severely immunosuppressed. ART regimens at initiation were 
AZT/D4T/ABC+3TC+NVP (84%), AZT/D4T/ABC+3TC+EFV (14%) and others (2%). 
With a median time on ART of 2.6 years [IQR 1.4–3.8], 1449 (71%) children were still on 
ART at the facility at the end of the observation period, 437 (21%) transferred to another 
facility, 108 (5%) were known deaths and 41 (2%) were LTF (Fig. 1). KM estimates 1 year 
after ART initiation were 3% (95% CI: 3–4%) for death and 1% (95% CI: 1–2%) for LTF. 
Significantly higher 1 year KM estimates for death were observed among children <18 
months old 1 and 2 years after ART initiation (1-year KM estimates: <18 months: 8%, 18–
59 months: 4%, ≥5 years: 3%; 2-year KM estimates: <18 months: 10%, 18–59 months: 5%, 
≥5 years: 4%; log-rank P value = 0.004). No statistically significant differences were 
observed for LTF after ART initiation by age group. KM estimates 2 years after ART 
initiation were 5% (95% CI: 4–6%) for death and 2% (95% CI: 1–3%) for LTF.
Factors Associated With Death and LTF Among pre-ART Children
Multivariate competing risks models for known death among pre-ART children are 
presented in Table 3. Factors associated with an increased hazard for death among this group 
included being <18 months old versus ≥5 years (adjusted subhazard ratio [aSHR] = 4.4, 95% 
CI: 2.9–6.8), being severely malnourished versus not malnourished (aSHR = 1.9, 95% CI: 
1.1–3.2), WHO stage IV and missing versus WHO stage I (aSHR = 4.1, 95% CI: 2.0–8.4; 
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aSHR = 3.7, 95% CI: 1.9–7.4, respectively) and no recorded CD4+ (aSHR = 3.0, 95% CI: 
1.9–4.6). Children who entered care through PMTCT programs had a lower risk of death 
versus those from voluntary counseling and testing (aSHR = 0.50, 95% CI: 0.25–1.0]. Pre-
ART children had a higher hazard of being LTF if they were <18 months old versus ≥5 years 
(aSHR = 1.6, 95% CI: 1.0–2.4) and had a missing WHO stage versus WHO stage I (aSHR = 
2.4, 95% CI: 1.6–3.6) (results not shown). A lower hazard for being LTF was observed 
among pre-ART children with more advanced disease (WHO stage III versus WHO stage I 
aSHR = 0.48, 95% CI: 0.31–0.75), severe immunosuppression versus none (aSHR = 0.25, 
95% CI: 0.12–0.54, respectively) and those attending facilities located in rural versus urban 
settings (aSHR = 0.71, 95% CI: 0.53–0.97) (results not shown).
Factors Associated With Death and LTF Among Children on ART
Multivariate Cox proportional models for known death among children on ART are 
presented in Table 3. Factors associated with an increased hazard for death among children 
on ART included children <18 months versus ≥5 years (adjusted hazard ratio [aHR] = 2.1, 
95% CI: 1.3–3.6), severe malnutrition versus not malnourished (aHR = 3.2, 95% CI: 1.3–
8.1), advanced WHO stage and missing versus WHO stage I (aHRstageII = 3.6, 95% CI: 1.3–
9.6; aHRstageIII = 2.6, 95% CI: 0.96–6.8; aHRstageIV = 9.8, 95% CI: 3.5–27.4; 
aHRstage missing = 6.0, 95% CI: 1.8–19.6) and severe immunosuppression versus no evidence 
of immunosuppression (aHR = 2.3, 95% CI: 1.7–3.3). No associations were observed with 
LTF among children on ART.
DISCUSSION
Our results demonstrate very high retention among a cohort of 3244 HIV-infected children 
enrolled in care at 39 health facilities in Rwanda. Among pre-ART children, we found that 
the 1-year cumulative incidence for death and LTF were 4% and 5%, respectively, 
considerably lower than the rates of 7–10% mortality and 10–20% LTF reported among 
children in HIV care in Cote d’Ivoire7 and the Democratic Republic of Congo.11 Overall, 
2035 (63%) children in care were initiated on ART, of whom 3% died and only 1% were 
LTF 1 year after ART initiation. Although the proportion of documented deaths among 
children on ART is similar to other programs in sub-Saharan Africa,3–5,10,11,20,21 the 
proportion LTF is substantially lower than what has been previously described in the region 
(range 7% to 23%).4,10,11,20,21
There are several reasons that could explain the high rates of retention observed in this study 
compared with other sub-Saharan African countries. First, it is noteworthy that high rates of 
retention have also been observed among adults on ART in Rwanda.22 The prevalence of 
HIV in Rwanda (3%) is considerably lower than many other sub-Saharan Africa countries, 
ART coverage among children is estimated to be 68%1 and the success of the PMTCT 
program has substantially reduced the number of new HIV infections in infants in recent 
years.23 Other factors that might have contributed to the high rates of retention among 
children in Rwanda are a good mentoring system for clinic staff, which was intensified 
during decentralization, a strong defaulter tracking system linking the facilities and the 
communities through peer educators, a regular drug and commodities supply system with 
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very limited stock outs and an efficient monitoring and evaluation system. In fact, the good 
documentation of children in this cohort transferring to another facility may also contribute 
to the low rates of LTF in pre-ART and ART children. However, it is important to note that 
the data available could not confirm whether these children were successfully engaged in 
care at another facility and whether there were treatment interruptions during this process. 
As a result, it is possible that the rates of LTF could indeed be higher than reported here.
Given that mortality and LTF are poorly understood during the pretreatment phase of HIV 
care among children, we examined the factors associated with these outcomes among pre-
ART children. Among this group, those entering care through PMTCT had half the risk of 
death of those identified through voluntary testing and counseling services. This finding 
supports the importance of linking PMTCT programs to pediatric HIV services to optimize 
pediatric outcomes. The hazard of LTF was lower among those with advanced HIV disease, 
as the sickest patients initiated ART. Additionally, we observed a lower hazard of LTF 
among those in rural settings, probably due to better links between the community and the 
health facility. LTF is a heterogeneous mix of withdrawals from care as well as 
undocumented transfers and deaths.24 Our findings suggest that in this cohort, those LTF are 
most likely to be either undocumented transfers or withdrawals, as their healthier disease 
status at enrollment suggests they are less likely to be undocumented deaths. The finding 
that healthier children are more likely to be lost is consistent with results from some adult 
cohorts, which have shown greater loss among subjects with less advanced disease at 
enrollment.25,26 We speculate that parents as well as health providers likely prioritize 
keeping children in care when they are receiving ART compared with children who are only 
being monitored prior to initiation. Earlier treatment of children, even among those with less 
advanced disease, could be a strategy to improve retention.
Similar to other studies in the region, younger age was strongly associated with death among 
pre-ART children and children on ART, highlighting the particular vulnerability of HIV 
children <18 months and the need to rapidly initiate ART.4,6,10,27,28 Initiating children on 
ART at a younger age could have potential benefits both for survival and program retention. 
The 2010 WHO ART guidelines for infants and children recommend that all patients <24 
months should be started on ART immediately regardless of CD4 count or clinical staging. 
Earlier treatment initiation is also now being recommended in older children.29 As expected, 
severe malnutrition and advanced HIV disease were also associated with higher risk of death 
in this cohort, in keeping with other studies.4,7,10
We observed a steady increase in the number of children enrolling into care and initiating 
ART from 2004 to 2007, with a decrease in new enrollments and ART initiations after 2008. 
Although we cannot fully explore these trends with the available data, we hypothesize that 
these findings reflect decreasing numbers of new pediatric infections as a result of wider 
access and the success of PMTCT services. Recent data from the Rwanda Ministry of Health 
estimates that 98% of all pregnant HIV-positive mothers attending PMTCT services in 
Rwanda receive antiretroviral treatment.23 Interestingly, a high proportion of children in our 
study entered care through non-PMTCT services. Rwanda has recommended systematic 
HIV testing for all children of unknown HIV status in pediatric wards, malnutrition and 
tuberculosis units as well as at other entry points in order to identify HIV-positive children 
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for enrollment into care.23 Furthermore, an additional explanation could be that the facilities 
included in the analysis were not enrolling as many HIV-infected children in more recent 
years as a result of decentralization and altered referral patterns. It is therefore possible that 
fewer children are newly enrolling in care at the facilities included in this analysis in the 
period after 2008 as a result of more facilities offering pediatric HIV services in Rwanda.
There are several important strengths of this analysis. First, this analysis includes more than 
3000 children from 39 health facilities in different settings and levels of care from 2004 to 
2010. Secondly, this analysis fills an important gap in the knowledge regarding outcomes of 
HIV-infected children before ART initiation who are enrolled in large scale HIV care and 
treatment programs. Finally, although this analysis used routinely collected data, there was 
good documentation of deaths, which, as noted above, may have contributed to a more 
accurate accounting for LTF and may also explain the somewhat high rates of death in 
children who were not on ART, particularly among younger children.
There are also limitations to this analysis, including missing data for individual subjects and 
lack of CD4+ percentage for all children <5 years old. These data were collected as part of 
routine clinical care at public facilities, so there is a high proportion of missing data 
compared with research studies. Another limitation is the lack of confirmation that children 
who were transferred to care to other facility did in fact enroll in care, so a subset of those 
transfers could indeed be LTF. Finally, while these sites represent 12% of facilities providing 
ART Rwanda and almost one-third of children in care by June 2011, results might not be 
generalizable to all sites in Rwanda, although we include facilities from different settings 
and type of care.
Overall, this study highlights the success of the Rwanda national program to rapidly scale-up 
and decentralize access to pediatric HIV care and treatment while maintaining very high 
retention rates after ART initiation. Our results also emphasize the need to optimize transfers 
of care, improve documentation of transfers across sites and ensure uninterrupted treatment 
during this process. Younger children continue to be particularly vulnerable, underscoring 
the urgent need for early identification and engagement in long-term HIV care and 
treatment.
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FIGURE 1. 
Outcomes among 3244 HIV-infected children <15 years of age enrolled in HIV care and 
treatment in Rwanda, January 2004 to June 2010.
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TABLE 3
Factors Associated With Documented Death Among HIV-infected Children <15 Years of Age Enrolled in 
Care and on Antiretroviral Treatment in the Survival Analyses
Pre-ART*
(N = 3244)
ART†
(N = 2035)
aSHR 95% CI aHR 95% CI
Age
  <18 mo 4.4 2.9–6.8 2.1 1.3–3.6
  18–59 mo 1.2 0.77–1.7 1.3 0.93–1.8
  ≥5 yr 1 1
Care entry points
  VCT 1 — —
  PMTCT 0.50 0.25–1.0 — —
  TB/HIV — — —
  PICT 1.06 0.72–1.6 — —
Malnutrition‡
  Not malnourished
  (Z score > −2)
1 1
  Moderately
  malnourished
  (−2 ≥ Z score ≥−3)
0.72 0.31–1.6 0.29 0.06–1.4
  Severely
  malnourished
  (Z score < −3)
1.9 1.1–3.2 3.2 1.3–8.1
  Missing 1.7 0.97–2.8 2.4 0.98–5.9
WHO stage
  Stage I 1 1
  Stage II 1.2 0.6–2.6 3.6 1.3–9.6
  Stage III 1.7 0.94–3.2 2.6 0.96–6.8
  Stage IV 4.1 2.0–8.4 9.8 3.5–27.4
  Missing 3.7 1.9–7.4 6.0 1.8–19.6
Immunodeficiency§
  No evidence 1 1
  Evidence of
  immunodeficiency
1.1 0.65–1.7 0.9 0.62–1.3
  Severe immunode-
  ficiency
1.6 0.93–2.8 2.3 1.7–3.3
  Missing 3.0 1.9–4.6 1.3 0.68–2.7
*Competing risk using subdistribution hazards models (adjusted subdistribution hazards ratios [aSHRs]).
†Cox proportional hazards models (adjusted hazard ratios [aHRs]).
‡Weight-for-age Z scores were calculated based on the Centers for Disease Control and Prevention standards [19].
§
Based on the Centers for Disease Control and Prevention age-adjusted CD4 count classification [18].
VCT indicates voluntary counseling and testing; TB, tuberculosis; PICT, provider-initiated counseling and testing; —, too few to compare.
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